Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
Public ClinicalTrials.gov record NCT00900146. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.
Study identification
- NCT ID
- NCT00900146
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 556 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 74 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2009
- Primary completion
- Oct 31, 2010
- Completion
- Oct 31, 2010
- Last update posted
- Feb 19, 2012
2009 – 2010
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Anasazi Internal Medicine | Phoenix | Arizona | — | — |
| Whittier Institute of Diabetes | La Jolla | California | — | — |
| Novartis Investigative Site | Los Gatos | California | — | — |
| Novartis Investigative Site | Santa Monica | California | 90404 | — |
| Orange County Research Center | Tustin | California | — | — |
| Novartis Investigative Site | Atlanta | Georgia | — | — |
| Deaconess Clinic | Evansville | Indiana | — | — |
| Novartis Investigative Site | Jackson | Mississippi | — | — |
| Novartis Investigative Site | Picayune | Mississippi | — | — |
| Novartis Investigative Site | Trenton | New Jersey | — | — |
| Diabetes Research Center | Columbus | Ohio | — | — |
| Tri-State Medical Group | Beaver | Pennsylvania | — | — |
| Preferred Primary Care Physicians | Pittsburgh | Pennsylvania | — | — |
| Novartis Investigative Site | Columbia | South Carolina | — | — |
| R/D Clinical Research | Lake Jackson | Texas | — | — |
| Novartis Investigative Site | Pasadena | Texas | — | — |
| Novartis Investigative Site | San Antonio | Texas | — | — |
| Medical Research Initiatives Inc | Virginia Beach | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00900146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2012 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00900146 live on ClinicalTrials.gov.